A committee of advisors to the U.S. Food and Drug Administration (FDA) dealt a blow to the burgeoning field of psychedelic medicine by recommending against the approval of MDMA-assisted therapy as a treatment for PTSD. MDMA, also known as ecstasy, has been studied for over a decade as a potential treatment for mental health conditions. The therapy in question involved administering MDMA capsules to patients undergoing psychotherapy sessions with a licensed professional. Despite some early promise, the FDA’s panel voted 10-1 against approval, raising concerns about the drug’s safety and effecti…
